Selank
A synthetic peptide analog of tuftsin with anxiolytic and nootropic properties, developed in Russia.
What is Selank?
Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence for stability. Developed at the Institute of Molecular Genetics in Russia, it is approved there as a prescription anxiolytic (anti-anxiety) medication. It is discussed for its calming effects without the sedation or dependency associated with traditional anti-anxiety medications.
What Selank Is Investigated For
Selank is investigated primarily for generalized anxiety disorder, stress-related cognitive performance, and immune modulation, and the strongest evidence is for anxiolytic effect — it is approved in Russia as a prescription anxiolytic based on clinical trials at the Institute of Molecular Genetics, including comparator work versus phenazepam. The honest caveats are significant: the efficacy literature is predominantly Russian-language and closely connected to the development program, independent Western replication is thin, and approved Russian protocols run only 10–14 days so long-term safety is uncharacterized. The mechanism itself is also unresolved — anxiolytic effects are attributed variously to GABAergic modulation, serotonergic metabolism, BDNF upregulation, and tuftsin-derived immunomodulation, with no clear hierarchy. Selank is not FDA-approved, and research-chemical-channel product varies substantially from the Geropharm pharmaceutical-grade material the trials used.
History & Discovery
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow in the 1990s, from the same research lineage that produced Semax. The team, again including Nikolai Myasoedov and colleagues, started from tuftsin — a naturally occurring immunostimulatory tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of immunoglobulin G — and appended a proline-glycine-proline tail to produce the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. The PGP tail is the same structural motif that stabilizes Semax against proteolysis and enables meaningful half-life after intranasal delivery. The unusual claim about Selank, at least versus more conventional anxiolytics, is that the researchers were targeting anxiety through an immunopeptide rather than a GABA-centric pathway — tuftsin's immunomodulatory activity was the original pharmacologic hook. Downstream Russian clinical work added GABAergic, serotonergic, and BDNF-modulation data. Selank was subsequently registered in Russia as a prescription anxiolytic (manufactured by Geropharm under the brand Selank) for generalized anxiety disorder and neurasthenia. The supporting clinical literature is predominantly Russian-language and connected to the development program, a pattern shared with Semax and Cerebrolysin. Outside Russia and a handful of CIS countries, Selank is not an approved medicine. In the Western nootropic community it has circulated via research-chemical suppliers since the 2010s.
How It Works
Selank works by modulating GABA, the brain's primary calming neurotransmitter, and by influencing serotonin metabolism. It essentially helps your brain's natural calming systems work more effectively without forcing them into overdrive.
Selank modulates the GABAergic system by allosterically enhancing GABA-A receptor sensitivity. It influences serotonin metabolism by affecting the expression of enzymes involved in tryptophan-serotonin conversion. It also modulates the expression of BDNF and its receptor, providing neuroprotective effects. As a tuftsin analog, it retains immunomodulatory properties, influencing IL-6, T-helper cell balance, and other immune parameters.
Evidence Snapshot
Human Clinical Evidence
Moderate (primarily Russian literature). Approved in Russia for generalized anxiety disorder.
Animal / Preclinical
Strong. Extensive animal data on anxiolytic effects, GABA modulation, and immune function.
Mechanistic Rationale
Strong. GABAergic modulation is a well-established mechanism for anxiolytic effects.
Research Gaps & Open Questions
What the current literature has not yet settled about Selank:
- 01Western, English-language, independently funded human trials — the efficacy literature is heavily Russian and heavily connected to the development program; independent replication in Western clinical contexts is thin.
- 02Long-term safety beyond the 2–3 week windows used in approved Russian protocols — chronic daily use over months or years has not been systematically studied.
- 03Head-to-head comparisons with SSRIs or benzodiazepines at clinically meaningful durations — a few Russian comparator trials exist (vs. phenazepam), but methodology and duration are limited.
- 04Controlled trials for off-label nootropic use in healthy individuals — approved indication is generalized anxiety, not cognitive enhancement in healthy adults.
- 05Pharmacokinetics and dose-response in diverse populations — most available data is in Russian clinical cohorts.
- 06Mechanistic resolution — whether the primary anxiolytic effect is GABAergic, immunomodulatory, serotonergic, or BDNF-mediated remains unresolved; multiple mechanisms are reported without clear hierarchy.
Forms & Administration
Selank is administered intranasally (nasal spray). Protocols should be determined by a qualified clinician.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Approved Russian clinical protocols use 0.15% intranasal solutions delivered at roughly 900 mcg per dose (three drops per nostril) up to 2,700 mcg/day total for generalized anxiety disorder. In forum-described nootropic protocols, 250–750 mcg per dose, 1–3 times daily, is the most commonly cited range, with total daily exposure typically between 500 mcg and 2,000 mcg. Clinical studies in Russia have used up to 2,700–3,000 mcg/day under medical supervision.
Frequency
Intranasal dosing is typically split into 2–3 administrations across the day. Users often dose in the morning and again before stress-provoking situations. Selank has a short plasma half-life (minutes), but subjective anxiolytic effects are described as lasting several hours, suggesting downstream receptor and gene-expression changes outlast the peptide itself. In approved Russian clinical protocols for generalized anxiety, daily dosing is continued across a 10–14 day course.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Russian medical protocols typically run 10–14 days for acute anxiety indications. Some protocols extend to 2–3 weeks with tapering. Forum users often describe episodic use during high-stress periods rather than chronic daily administration. Long-term continuous use (months) is not well studied and is not part of the approved clinical protocol.
Protocol Notes
Selank was designed for intranasal delivery, which leverages the nasal mucosa's olfactory and trigeminal pathways for direct CNS access while bypassing first-pass metabolism. Oral, sublingual, and injected routes are uncommon in the clinical literature and are not interchangeable with intranasal dosing. Practical administration involves 2–3 drops per nostril from a dropper bottle, head tilted slightly back, with gentle sniffing to distribute across the upper nasal cavity. Nasal irritation — dryness, congestion, minor bleeding — is the most common adverse effect, particularly with chronic use. Alternating nostrils or pausing for mucosal recovery is a common adjustment. Sourcing is a practical concern. Pharmaceutical-grade Russian product (Geropharm Selank 0.15%) is the reference used in clinical studies. Research-chemical-channel Selank varies substantially in actual peptide content and preservative systems. Unverified sources cannot be assumed to match the clinical-grade material.
Selank is not FDA-approved in the United States for any medical indication. It is approved in Russia and several CIS countries under their national regulatory framework. Russian-approved status does not constitute FDA approval or Western regulatory endorsement. Any use outside approved indications, or outside jurisdictions where it is approved, is not authorized medical care.
Timeline of Effects
Onset
Subjective anxiolytic effects — reduced rumination, lower baseline tension, improved composure — are commonly described within 15–45 minutes of an intranasal dose. Some users report effects within minutes, which is plausible given intranasal CNS access but has not been rigorously characterized in controlled trials. Russian clinical trials typically assess outcomes at 3–5 days of continuous use rather than acute post-dose.
Peak Effect
Peak subjective effect is typically described within 1–3 hours of administration. Cumulative clinical benefit in Russian anxiety trials is typically assessed at 7–14 days of continuous use, reflecting a pattern where repeated dosing appears more effective than single doses for sustained anxiolysis — consistent with downstream gene-expression and neurotrophic effects rather than acute receptor occupancy.
After Discontinuation
Acute effects fade within hours of the last dose. Russian clinical reports describe no meaningful withdrawal syndrome or rebound anxiety — in contrast to benzodiazepines — which is part of the argument for Selank's clinical positioning. Longer-term changes from accumulated BDNF-mediated signaling may persist for days to weeks. No documented dependence or tolerance in approved-course use.
Common Questions
Who Selank Is NOT For
- •Pregnancy — no controlled safety data; the approved Russian product labeling lists pregnancy as a contraindication.
- •Breastfeeding — no data on transfer into breast milk or effects on the nursing infant.
- •Known hypersensitivity to Selank or to components of the intranasal vehicle (benzalkonium chloride and related preservatives appear in some formulations).
- •Severe nasal mucosal disease, chronic rhinitis, or recent nasal surgery — intranasal delivery is poorly tolerated or disrupted in these contexts.
- •Concurrent use of benzodiazepines or other strong GABAergic sedatives without clinician oversight — animal data show Selank potentiates diazepam's anxiolytic effect, and the clinical implication in humans has not been quantified.
- •Pediatric use outside specific Russian-approved pediatric indications — safety data in children is limited to registered pediatric protocols in Russia.
Drug & Supplement Interactions
Documented clinical drug interactions for Selank are limited. The most plausible theoretical interaction is with GABAergic agents — benzodiazepines, barbiturates, certain anticonvulsants, and Z-drugs — because animal studies show Selank potentiates diazepam's anxiolytic effect. The clinical magnitude of this interaction in humans has not been quantified, and caution with combined use is warranted until better data exists. Because Selank also modulates serotonergic metabolism, concurrent use with SSRIs, SNRIs, MAOIs, or triptans could in principle shift pharmacologic balance, though no specific adverse interaction has been published. Combining with other nootropic peptides (Semax, Cerebrolysin, Noopept) is common in Russian clinical practice and in forum culture, but these combinations have not been studied for additive safety endpoints. Selank's short plasma half-life and small doses reduce the likelihood of pharmacokinetic interactions via CYP enzymes or protein binding; there is no documented concern with typical cardiovascular or endocrine medications. Patients on any regular psychiatric medication should disclose Selank use to their prescribing clinician, as clinical experience in Western psychiatric populations is essentially absent.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved in the US
- • Most clinical data from Russian studies
- • May interact with GABAergic medications
What We Don't Know
Western clinical trial data is very limited. Interactions with common Western medications are not well characterized.
Legal Status
United States
Selank is not FDA-approved for any medical indication. It is not a controlled substance, not a recognized dietary supplement ingredient, and not a legal cosmetic ingredient. In practice, Selank is sold in the US primarily through research-chemical suppliers (not authorized for human use), with more limited historical availability via compounding pharmacies. The FDA's ongoing reassessment of peptides eligible for 503A compounding makes that pathway uncertain. Legal gray zone: not prohibited, but not approved, and not a legitimate OTC ingredient.
International
Approved as a prescription anxiolytic in Russia (Geropharm) and registered in several CIS countries including Belarus, Kazakhstan, and Ukraine for generalized anxiety disorder and neurasthenia. Not approved by EMA, MHRA, TGA, or Health Canada. Regulatory posture across the EU and UK ranges from research-chemical availability to active enforcement against unapproved sale depending on jurisdiction.
Sports & Competition
Selank is not currently listed by name on the WADA Prohibited List. However, WADA's S0 category prohibits any substance 'not approved by any governmental regulatory health authority for human therapeutic use' — which does not strictly apply to Selank given its Russian approval, but governing bodies may still interpret ambiguously. Athletes subject to WADA code should check with their national anti-doping authority before use and should not assume safety.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Selank is FDA-approved.
Reality
Selank is not FDA-approved for any indication in the United States. It is approved as a prescription anxiolytic in Russia and several CIS countries under their national regulatory frameworks. Russian approval is not equivalent to FDA approval — the evidence base supporting Russian registration does not meet the trial design, independence, or replication standards typically required by the FDA.
Myth
Selank is just a Russian benzodiazepine.
Reality
Selank is not a benzodiazepine and does not bind the benzodiazepine site on the GABA-A receptor in the classical way. It modulates GABAergic signaling indirectly and works through multiple additional pathways — tuftsin-derived immunomodulation, serotonin metabolism, BDNF upregulation. Mechanism, dependence profile, and subjective effect differ meaningfully from benzodiazepines.
Myth
Selank has no side effects because it is a 'natural' peptide.
Reality
Selank is a synthetic heptapeptide. The PGP stabilizing tail is not a naturally occurring modification of tuftsin. Side effects reported in clinical use include nasal irritation, fatigue, and mild sedation at higher doses. Long-term safety has not been established.
Myth
Selank is safe to combine with SSRIs and benzodiazepines without any concern.
Reality
Combinations with serotonergic and GABAergic drugs are mechanistically plausible interaction points. Animal data show Selank potentiates diazepam's anxiolytic effect. Clinical safety of these combinations has not been systematically studied in Western populations and should be treated with caution.
Myth
All Selank sold online is equivalent to the Russian pharmaceutical product.
Reality
Research-chemical-channel Selank varies substantially in purity, actual peptide content, and preservative systems. The Russian clinical literature is based on Geropharm pharmaceutical-grade product. Unverified sources cannot be assumed to deliver comparable dose or safety.
Published Research
30 studiesSelank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank
Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank
The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress
Functional Connectomic Approach to Studying Selank and Semax Effects
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress
State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
[COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.]
Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism
Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
[Optimization of the treatment of anxiety disorders with selank]
The influence of Selank on the parameters of the hemostasis system, lipid profile, and blood sugar level in the course of experimental metabolic syndrome
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation
[Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank]
The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action
[Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]
[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application]
Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress
The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats
[The characteristics of the anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism in the brain of rats with chronic deprivation of serotoninergic system activity]
Popular Stacks Including Selank
Quick Facts
- Class
- Nootropic Peptide
- Tier
- C
- Evidence
- Emerging
- Safety
- Moderate Data
- Updated
- May 2026
- Citations
- 30PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.